Connect with us

Health

Urban city design might help promote heart health

Published

on



ANI |
Updated:
May 22, 2021 19:20 IST

Sophia Antipolis [France], May 22 (ANI): The conclusion of a new paper suggests that cities harbor a dangerous cocktail of environmental stressors which politicians must tackle to save lives and preserve health.
The paper was published in the European Heart Journal, a journal of the European Society of Cardiology (ESC).
“By 2050, three in four people will live in cities, where up to 80 per cent of energy is consumed and 70 per cent of greenhouse gases are emitted,” said study author Professor Thomas Munzel of the University Medical Centre Mainz, Germany. “There are limited actions that individuals can take to protect themselves from pollutants so politicians and policymakers need to take on this responsibility.”
Cardiovascular diseases are the leading cause of mortality in Europe, accounting for 47% and 39% of all deaths in women and men, respectively.2 The World Health Organization (WHO) regional office for Europe has advocated urban planning which supports cycling and walking and improves air quality. The proposal, supported by the ESC, is a step towards meeting the WHO’s target of a 25% per cent relative reduction in premature mortality from cardiovascular disease by 2025 (compared to 2010).
“While cities have been an engine of innovation and wealth, they are also a source of pollution and disease,” states today’s paper. It sums up the evidence for the connections between bad air, noise, temperature, outdoor light and cardiovascular disease.

Air pollution is responsible for around 800,000 fatal illnesses per year in Europe, of which around half are heart attacks and strokes. Transport emissions are the largest contributor to air pollution in cities around the world. Similarly, the dominant source of noise is road traffic, which increases the risk for ischaemic heart disease. It has been estimated that long-term exposure to transportation noise is responsible for 48,000 new cases of ischaemic heart disease each year in the EU.
Nocturnal light pollution has been linked with hospitalisation and death from coronary heart disease. Meanwhile, concrete urban areas absorb and re-emit the sun’s heat, leading to rising temperatures. These heat island effects have been connected with deaths during heatwaves, which can be mitigated with vegetation.
Environmental stressors cluster together and actions are needed which combat them all. “Transitioning to cities that promote local living and active and sustainable mobility is increasingly recognised as providing co-benefits for health and the environment”>environment by creating more sustainable and liveable cities,” states the paper.
City planning is now recognised as one way to tackle adverse health outcomes. Designs include car-free areas and compact cities which shorten travel distances. Limiting car use while increasing public and active transportation (walking and cycling) would promote heart health by reducing air pollution, noise, and heat island effects and increasing physical activity.
The authors call for “a radical rethink about how we organise the way we live in the future in order to protect human and planetary health”.
Professor Munzel said: “Individuals can avoid polluted areas and wear ear plugs but real change requires commitment from politicians. It is expected that metropolitan areas will house an ever-greater share of the world’s population in years to come. Now is the time to design cities which promote rather than damage health.” (ANI)

Advertisement

Health

Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, treatment | Health

Published

on

By

Adenoiditis is a type of health condition wherein the adenoids (tissue behind the nose and above the throat) gets inflamed and it is common among children and leads to problems like snoring, mouth breathing, recurrent ear infections, decreased hearing, difficulty in breathing, cracked lips, runny nose and bad breath. Adenoiditis occurs when there is inflammation of the adenoid tissue resulting from infection, allergies or irritation from stomach acid as a component of laryngopharyngeal reflux (LPR).

Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, side effects, treatment (Photo by Twitter/DrMary_Alphonse)
Adenoiditis: Causes, who is at risk, signs and symptoms, diagnosis, side effects, treatment (Photo by Twitter/DrMary_Alphonse)

In an interview with HT Lifestyle, Dr Nitty Mathew, Senior Specialist – ENT at Aster CMI Hospital, revealed, “Adenoiditis is usually caused by an infection of adenoids. Adenoids become apparent by 2 years of age and regress in size after 8 years. If these remain swollen for a prolonged time, then they can become problematic.”

Highlighting who is at risk of developing adenoiditis, she shared that since adenoids usually shrink by adulthood, children are most susceptible to its infection. They can be more prone to developing adenoiditis if the child is

● Bottle fed

● Breast fed in lying down position

Advertisement

● Have an infection near the nose or throat

● Suffering from an allergy

According to her, the symptoms of adenoiditis include:

● Stuffy and blocked nose

● Snoring

Advertisement

● Sleep apnea

● Cracked lips, dry mouth

● Glue ear

● Ear pain and infections

● Swollen neck glands

Advertisement

She said, “To diagnose adenoiditis, your doctor will conduct a check-up of your child’s nose, ears, mouth and throat. In case the symptoms are worse, your doctor may also suggest he/she undergo an X-ray to see degree of enlargement of adenoids and obstruction of nasal airway.”

Talking about the side effects of adenoiditis, Dr Nitty Mathew pointed out that the complications of untreated adenoiditis include –

● Runny nose

● Recurrent ear infections, decreased hearing

● Dry mouth, Dental caries

Advertisement

● Speaking with a nasal tone

● Adenoid facies

The health expert added, “Adenoid facies is defined as the open -mouthed appearance in children, associated with a narrow nose, shortened upper lip, narrow palate, high palatal vault and dental crowding.” She concluded, “Usually by 8years of age adenoids regress, but keeping good hygiene can prevent repeated infections. Mild symptoms warrants only supportive treatment, but if your doctor suspects any bacterial infection then the child will have to be treated with antibiotics and then kept on nasal sprays to decrease the size of adenoids. In case the medications are not bringing intended relief of symptoms, then a surgery called adenoidectomy to remove the enlarged adenoids will have to be done.”

Advertisement
Continue Reading

Health

Researchers explain: What causes long Covid breathing problems

Published

on

By

Researchers at Stanford University have found that people are experiencing breathing problems post Covid-19 due to a condition known as lung fibrosis in which the damaged lungs form scar tissue, that makes it difficult for the lungs to expand and contract.

The research showed that overactivity of genes that regulate inflammation and immune responses leads to lung fibrosis.

Long Covid cases can be severely debilitating and resistant to treatment, said Gerlinde Wernig, Assistant Professor of pathology, at Stanford University.

What`s worse, lung function can continue to decline, even without a new Covid-19 infection, Wernig said.

Advertisement

The finding published in the Proceedings of the National Academy of Sciences offers hope that, one day, targeted drugs could intervene to quell the genes behind the damage.

In the study, the team started by looking at lung tissue samples from five Covid-19 patients who had symptoms of the disease — such as shortness of breath — for one or more months. The lungs of people who had symptoms after infection with SARS-CoV-2 looked like the lungs of people with end-stage pulmonary fibrosis.

By analysing single cells from the patients` tissue samples, the scientists also saw similarities in the pattern of RNA production — which can hint a cell`s overall function — between samples of tissue from long Covid patients and samples from patients with pulmonary fibrosis.

“We saw this same pattern across all human Covid lung samples,” Wernig said.

As with other lung infections, the initial Covid-19 infection in the lungs kicked off an inflammatory process. In the case of long-Covid patients, however, the immune dysfunction keeps going long after the virus is gone — similar to what happens in chronic pulmonary fibrosis.

Advertisement

To test whether lung fibrosis could be firmly connected to Covid infections, they looked at lung fibrosis in mice infected with a SARS-CoV-2-like virus and found significant increases in fibrosis and immune dysfunction.

“Innate immune cells go crazy after that infection,” Wernig said, referring to the part of the immune system that forms the first line of defence against pathogens.

In a mouse model engineered to more closely represent human biology, researchers showed that, when the mice contracted SARS-CoV-2, scarring in the lung tissues shot up, as did levels of immune cells interleukin-6, CD47 and pJUN. There was also a bright side to these experiments.

“When we did the same experiments but blocked CD47 and Il-6, we saw very little fibrosis,” Wernig said. “This hints at possible treatments for long Covid involving drugs that carry out targeted immune blockades.”

Also Read: Mumbai: All wards have Covid-19 cases; only one critical

Advertisement

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Continue Reading

Health

89Bio’s NASH drug meets main goals of mid-stage study, Health News, ET HealthWorld

Published

on

By

89Bio's NASH drug meets main goals of mid-stage study

New Delhi: Drug developer 89Bio Inc said on Wednesday its treatment for a liver disease called non-alcoholic steatohepatitis met the main goals of a mid-stage trial, sending its shares up 50 per cent in premarket trading.

The company’s experimental drug, Pegozafermin, demonstrated at least one-stage fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis in both trial doses.

89Bio said the data supports advancement to late-stage development.

Follow and connect with us on , Facebook, Linkedin, Youtube

Advertisement

Continue Reading

Trending